Beyond Docking: A Multitier Computational Pipeline for USP7 Inhibitor Optimization.
Serdar Durdagi1,2, Ehsan Sayyah1,2, Muhammet Eren Ulug1,2,3
1Lab for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, 34746, İstanbul, Türkiye.
Researchers identified novel Ubiquitin-specific protease 7 (USP7) inhibitors using computational methods. These compounds show promise for developing new cancer therapies targeting USP7.
Area of Science:
- Biochemistry
- Computational Chemistry
- Pharmacology
Background:
- Ubiquitin-specific protease 7 (USP7) is a critical enzyme in cellular processes like DNA repair and epigenetic regulation.
- USP7 plays a significant role in cancer progression, making it a key therapeutic target.
Purpose of the Study:
- To identify and optimize novel inhibitors of USP7 using a multi-tier computational strategy.
- To evaluate the anticancer potential and selectivity of the identified USP7 inhibitors.
Main Methods:
- Ligand-based virtual screening, molecular docking, and MD simulations were employed.
- MM/GBSA binding free energy calculations, binary QSAR modeling, and steered MD simulations were utilized.
- Cross-docking against USP family members assessed compound selectivity.
Main Results:
- High-affinity USP7 inhibitors were identified with docking scores below -8.0 kcal/mol.
- MD simulations and MM/GBSA calculations confirmed stability and interaction patterns.
- QSAR analysis predicted high therapeutic activity (normalized value > 0.5) for selected compounds.
Conclusions:
- The study successfully identified promising USP7 inhibitor candidates through comprehensive computational analysis.
- These compounds warrant further in vitro investigation for the development of advanced USP7-targeted cancer therapies.
More Related Videos
22:10Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
